Outcomes in Subpopulations from Pooled Phase 3 Clinical Studies of Oral Ibrexafungerp Versus Placebo in Patients with Vulvovaginal Candidiasis (VANISH 303 and 306)

In the United States (US), there are approximately 10 million office visits annually for vaginal symptoms, of which approximately 20-25% are vulvovaginal candidiasis (VVC). The current approved therapies for treatment of VVC are all azoles which are fungistatic. Here, we introduce oral ibrexafungerp (IBX), a novel triterpenoid antifungal, with fungicidal activity against a broad range of Candida species for treatment of VVC. The purpose of this research is to examine efficacy and safety; and subpopulation outcomes from two phase 3 clinical trials of oral IBX versus Placebo (PLC) in patients with vulvovaginal candidiasis (VVC) in a pooled analysis